Pharmaceutical Technologist - October 2006 - (Page 21)
// Findlay France favourable for generics, thanks to the government's
initiatives to reduce healthcare costs; its generics are poised for growth
as France has the lowest prices for drugs among its European counterpar ts.
Generic market share is set to experience explosive growth from 13% in 2004
to 23% in the coming years because of the attractive environment created by
government regulations. Generics form only 5.7% of current healthcare
spending and this is expected to rise to 10.2% by 2009. Generic drugs
manufacturers are finding France a haven for their low cost medicines.
Drugs catering to major therapeutics areas like cardiovascular, neurology,
anti-infectives and anti- inflammator y are all best sellers, and with many
blockbuster drugs facing the threat of patent expiration, the generic
business should post strong sales Figure 3 . Summary With reforms being
proposed by the French government to hold back its declining position in
the pharmaceutical sector, France is set to face tough times. Poor
relationships between the state and insurance firms, an ageing population,
spiralling costs and decreasing numbers of healthcare professionals are the
main issues impeding the reforms. France has to gear up to provide a more
attractive market for pharmaceutical investment. Strategies to effectively
iron- out the challenges that retard growth in the market are urgently
required. Though the healthcare system offers better care to patients, the
onus lies on the government to sustain its strong position in the
pharmaceutical market and continue to offer world class healthcare
services. PT Sylvia M. Findlay is a research analyst in pharmaceuticals
and biotechnology, healthcare EMEA at Frost & Sullivan UK . 21
www.ptemagazine.com
http://www.eurcoval.com
http://www.eurcoval.com
http://www.ptemagazine.com
Table of Contents for the Digital Edition of Pharmaceutical Technologist - October 2006
Market Watch
Contents
Editor's Comment
Q&A
News
Open Innovation Networks
Vive le France?
Morpheus
Pharmaceutical Technologist - October 2006
Pharmaceutical Technologist - October 2006 - (Page 1)
Pharmaceutical Technologist - October 2006 - Contents (Page 2)
Pharmaceutical Technologist - October 2006 - Contents (Page 3)
Pharmaceutical Technologist - October 2006 - Editor's Comment (Page 4)
Pharmaceutical Technologist - October 2006 - Editor's Comment (Page 5)
Pharmaceutical Technologist - October 2006 - Editor's Comment (Page 6)
Pharmaceutical Technologist - October 2006 - Editor's Comment (Page 7)
Pharmaceutical Technologist - October 2006 - News (Page 8)
Pharmaceutical Technologist - October 2006 - News (Page 9)
Pharmaceutical Technologist - October 2006 - News (Page 10)
Pharmaceutical Technologist - October 2006 - News (Page 11)
Pharmaceutical Technologist - October 2006 - Morpheus (Page 12)
Pharmaceutical Technologist - October 2006 - Morpheus (Page 13)
Pharmaceutical Technologist - October 2006 - Market Watch (Page 14)
Pharmaceutical Technologist - October 2006 - Market Watch (Page 15)
Pharmaceutical Technologist - October 2006 - Market Watch (Page 16)
Pharmaceutical Technologist - October 2006 - Market Watch (Page 17)
Pharmaceutical Technologist - October 2006 - Vive le France? (Page 18)
Pharmaceutical Technologist - October 2006 - Vive le France? (Page 19)
Pharmaceutical Technologist - October 2006 - Vive le France? (Page 20)
Pharmaceutical Technologist - October 2006 - Vive le France? (Page 21)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 22)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 23)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 24)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 25)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 26)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 27)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 28)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 29)
Pharmaceutical Technologist - October 2006 - Open Innovation Networks (Page 30)
Pharmaceutical Technologist - October 2006 - Q&A (Page 31)
Pharmaceutical Technologist - October 2006 - Q&A (Page 32)
Pharmaceutical Technologist - October 2006 - Q&A (Page 33)
Pharmaceutical Technologist - October 2006 - Q&A (Page 34)
Pharmaceutical Technologist - October 2006 - Q&A (Page 35)
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0908
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0708
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0508
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0308
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0108
https://www.nxtbook.com/nxtbooks/advanstaruk/pt1107
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0907
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0707
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0507
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0107
https://www.nxtbook.com/nxtbooks/advanstaruk/pte-mediakit07
https://www.nxtbook.com/nxtbooks/advanstaruk/pte1006
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0706
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0506
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0406
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0306
https://www.nxtbookmedia.com